ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Risk stratification schema for localized prostate cancer, according to the National Comprehensive Cancer Network (NCCN)

Risk stratification schema for localized prostate cancer, according to the National Comprehensive Cancer Network (NCCN)
Risk group Clinical/pathologic features
Very low
  • T1c AND
  • Grade group 1 AND
  • PSA <10 ng/mL AND
  • Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core AND
  • PSA density <0.15 ng/mL/g
Low
  • T1 to T2a AND
  • Grade group 1 AND
  • PSA <10 ng/mL AND
  • Does not qualify for very low risk
Favorable intermediate
  • No high or very high risk features
  • No more than one intermediate risk factor:
    • T2b to T2c OR
    • Grade group 2 or 3 
    • PSA 10 to 20 ng/mL

AND

  • Grade group 1 or 2

AND

  • Percentage of positive biopsy cores <50%
Unfavorable intermediate
  • No high or very high risk features
  • Two or three of the intermediate risk factors:
    • T2b to T2c
    • Grade group 2 or 3
    • PSA 10 to 20 ng/mL

AND/OR

  • Grade group 3

AND/OR

  • ≥50% of positive biopsy cores
High
  • No very high risk features

AND

  • T3a OR
  • Grade group 4 or 5 OR
  • PSA >20 ng/mL
Very high
  • T3b to T4 OR
  • Primary Gleason pattern 5 OR
  • Two or three high-risk features OR
  • >4 cores with Grade group 4 or 5
PSA: prostate-specific antigen.
Adapted from: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. Version 4.2018.
Graphic 118962 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟